Abstract:Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the western countries. The histological spectrum of NAFLD includes simple steatosis, steatohepatitis, fibrosis, cirrhosis and even hepatocellular carcinoma. Nuclear receptors are a large group of ligand-dependent transcription factors that sense the environmental and endogenous changes and regulate numerous physiological and pathological processes. Accumulating evidence has suggested that a dysregulation of nuclear receptors in NAFLD may effect on the metabolism of endogenous and exogenous chemicals in the liver. The current study was designed to systematically characterize the time-dependent modulation of nuclear receptors including the peroxisome proliferator-activated receptors (PPARs), the constitutive androstane receptor (CAR), the pregnane X receptor (PXR), the liver X receptor (LXR), and the farnesoid X receptor (FXR) in the progression of NAFLD. Male C57BL/6 mice fed by a high fat diet were used to induce NAFLD. Hepatic steatosis, lobular inflammation, progressive fibrosis, increased hepatocyte DNA synthesis, and liver tumor formation were observed at various time points in our mouse model. During the development of hepatic steatosis (8-16 weeks), PPARα was activated as indicated by its target genes as well as the elevated peroxisomal acyl-CoA oxidase activity. The mRNA level of Pparγ was also upregulated while Pparδ gene expression was significantly reduced during the development of hepatic steatosis. PXR target gene Cyp3a11 was consistently increased 3-4-fold in addition to the increased microsomal Cyp3a enzymatic activity at all stages of NAFLD. In contrast, CAR mediated Cyp2b10 gene expression was found increased only by week 12. LXRα target genes Abcg5 and Abcg8 were significantly elevated during the whole course of NAFLD. The mRNA of Fxr was downregulated at 24 and 32 weeks in high fat diet fed mice, which might correlate with the development of progressive fibrosis at the stage of steatohepatitis. The results of our study provided a systematic evaluation of the changes of nuclear receptors and their downstream chemicalmetabolism and transport enzymes in the progression of NAFLD.

Expression of Cytochrome P450 2a5 in A C57bl/6j Mouse Model of Nonalcoholic Fatty Liver Disease

Effects of Fatty Acids on CYP2A5 and Nrf2 Expression in Mouse Primary Hepatocytes

Expressions of Key Regulatory Genes of the Lipid Metabolism in Livers During the Development of Rat Non-alcoholic Fatty Liver Disease

Upregulation of Caveolin-1 and SR-B1 in Mice with Non-Alcoholic Fatty Liver Disease

Functional Proteomic Analysis of Nonalcoholic Fatty Liver Disease in Rat Models: Enoyl-coenzyme a Hydratase Down-Regulation Exacerbates Hepatic Steatosis

Ablation Of Cytochrome P450 Omega-Hydroxylase 4a14 Gene Attenuates Hepatic Steatosis And Fibrosis

Identification of gene expression patterns in rat model of nonalcoholic fatty liver disease

CYP3A suppression during diet-induced nonalcoholic fatty liver disease is independent of PXR regulation

Role of Nrf2 on the mechanism of nonalcoholic fatty liver disease in mice

The Role of Human Cytochrome P450 2E1 in Liver Inflammation and Fibrosis

Hepatocyte-specific NR5A2 deficiency induces pyroptosis and exacerbates non-alcoholic steatohepatitis by downregulating ALDH1B1 expression

5-Methoxyflavone Ameliorates Non-Alcoholic Fatty Liver Disease Through Targeting the Cytochrome P450 1A1.

Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease

Mechanism of High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease..

Cytochrome P450 Omega-Hydroxylase 4a14 Attenuates Cholestatic Liver Fibrosis

Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis

Progress in effects of nonalcoholic fatty liver disease on cytochrome P450 family and the possible related mechanism

The Expression Change of COX and CPT in Different Stages of Non-Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease changes the expression and activity of hepatic drug-metabolizing enzymes and transporters in rats

Expression of cyclooxygenase-2 in nonalcoholic fatty liver disease and its significance

The role of C5aR1-mediated hepatic macrophage efferocytosis in NASH